氯沙坦治疗肝硬化门脉高压的临床观察  

Observing the effect of losartan on hepatic cirrhosis portal hypertension

作　　者：潘超雄[1] 孙杰[1] 

机构地区：[1]广东医学院附属医院急救中心,广东湛江519000

出　　处：《河北医学》2004年第9期812-814,共3页Hebei Medicine

摘　　要：目的 :观察血管紧张素Ⅱ受体拮抗剂氯沙坦 (商品名科素亚 )降低肝硬化门脉高压的作用。方法 :2 5例肝硬化门脉高压患者每天口服氯沙坦 2 5～ 5 0mg ,历时 2～ 4周 ,应用多普勒超声分别测定治疗前后门静脉、脾静脉、肠系膜上静脉内径 ,并计算门静脉、脾静脉的血流量。结果 :治疗后门静脉内径明显缩小 ,从 (1 4 .1 8± 2 .1 1 )mm降到 (1 2 .1 1± 1 .87)mm(P <0 .0 1 ) ,血流量从 (1 1 85 .5 2± 81 2 .6 0 )ml/min降到 (6 41 .91± 390 .30 )ml/min (P <0 .0 1 ) ;脾静脉、肠系膜上静脉内径及其血流量也有所降低 ,无显著性意义。结论Objective: To observe the effects of losartan(an antagonist of agio tensin ∏) on reduction of hepatic cirrhosis portal hypertension . Method: Losortan was taken orally by 25 patients with hypatic cirrhosis portal hypertension at a daily dosage between 25mg and 50mg for 2 to 4 weeks.The internal calibre of PV,SPV,SMV were determined by doppler ultrasound before and after the treatment respectively. QPv,Qspv and Qsmv were calculated at the same time . Result: After the treatment,the internal calibre of PV significantly reduced from(14.18±2.11)mm to (12.11±1.87)mm(P<0.01);Qpv reduced from (1185.52±812.60)ml/min to(641.91±390.30)ml/min (P<0.01). The internal calibre of SPV,SMV as well as Qspv .Qsmv reduced too,but this change was not significant. Conclusion: Logartan has a certain effect on reduction of portal rein pressure.

关 键 词：肝硬化 门脉高压 药物治疗 

分 类 号：R575.21[医药卫生—消化系统]